Search

Your search keyword '"Federico Hinestrosa"' showing total 2 results
Start Over Author "Federico Hinestrosa" Journal journal of virus eradication
2 results on '"Federico Hinestrosa"'

1. Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting

Author

Charlotte-Paige Rolle, Vu Nguyen, Federico Hinestrosa, and Edwin DeJesus

Subjects
Simplification, Multi-tablet regimens, Highly treatment experienced, Microbiology, QR1-502, Public aspects of medicine, RA1-1270
Abstract

Background: Multi-tablet regimens (MTRs) are associated with increased adverse events and non-adherence. Single tablet regimens (STRs) plus boosted protease inhibitors (PIs) are a simplification option for MTR-treated patients; however, data is needed to validate this therapeutic strategy. Methods: This retrospective analysis included all HIV-1 infected patients seen at a single center from March 2016 to December 2017 who were switched from twice-daily (BID) regimens or regimens containing ​≥ ​3 pills daily to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF) plus darunavir (DRV) or rilpivirine/emtricitabine/tenofovir-alafenamide (RPV/F/TAF) plus DRV boosted with ritonavir or cobicistat (DRV/r-c). Eligible patients had baseline HIV-1 RNA

Published
2020
Full Text
View/download PDF

2. Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting

Author

Federico Hinestrosa, Vu Nguyen, Edwin DeJesus, and Charlotte-Paige Rolle

Subjects
0301 basic medicine, medicine.medical_specialty, Epidemiology, Immunology, Emtricitabine, Microbiology, Gastroenterology, Tenofovir alafenamide, Simplification, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Virology, Internal medicine, medicine, 030212 general & internal medicine, Darunavir, Original Research, business.industry, Elvitegravir, Cobicistat, Public Health, Environmental and Occupational Health, Highly treatment experienced, Multi-tablet regimens, QR1-502, Regimen, 030104 developmental biology, Infectious Diseases, chemistry, Rilpivirine, Ritonavir, Public aspects of medicine, RA1-1270, business, medicine.drug
Abstract

Background: Multi-tablet regimens (MTRs) are associated with increased adverse events and non-adherence. Single tablet regimens (STRs) plus boosted protease inhibitors (PIs) are a simplification option for MTR-treated patients; however, data is needed to validate this therapeutic strategy. Methods: This retrospective analysis included all HIV-1 infected patients seen at a single center from March 2016 to December 2017 who were switched from twice-daily (BID) regimens or regimens containing ​≥ ​3 pills daily to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF) plus darunavir (DRV) or rilpivirine/emtricitabine/tenofovir-alafenamide (RPV/F/TAF) plus DRV boosted with ritonavir or cobicistat (DRV/r-c). Eligible patients had baseline HIV-1 RNA

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results